- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Lixte Biotechnology: Aktionäre genehmigen neue Verwaltungsratsmitglieder und erweiterten Aktienplan | 1 | Investing.com Deutsch | ||
| 11.12. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Lixte Biotechnology Holdings, Inc.: LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities | 296 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic... ► Artikel lesen | |
| 03.12. | Lixte Biotechnology Holdings, Inc.: LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology | 253 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though... ► Artikel lesen | |
| 03.12. | Lixte Biotechnology Holdings, Inc.: LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers | 167 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all. It may be an amplifier... ► Artikel lesen | |
| 28.11. | NSE/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 25.11. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 25.11. | Lixte Biotechnology: Aktie gibt nach Übernahme von Liora deutlich nach | 2 | Investing.com Deutsch | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 25.11. | LIXTE Biotechnology acquires UK-based proton therapy developer Liora | 1 | Investing.com | ||
| 25.11. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment | 173 | GlobeNewswire (Europe) | Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25... ► Artikel lesen | |
| 12.11. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.09. | Lixte Biotechnology Holdings, Inc.: LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future | 327 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight... ► Artikel lesen | |
| 15.09. | Lixte Biotechnology: Führungswechsel und strategische Neuausrichtung nach Kursrallye | - | Investing.com Deutsch | ||
| 15.09. | BOCA RATON - Lixte Biotechnology refreshes leadership and diversifies assets | 2 | Investing.com | ||
| 15.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy | 434 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT)... ► Artikel lesen | |
| 11.09. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | LIXTE Biotechnology makes $2.6M initial purchase of digital currency | 1 | Seeking Alpha | ||
| 10.09. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions | 141 | GlobeNewswire (Europe) | BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 05.09. | 24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor | 297 | Newsfile | Denver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, underscores... ► Artikel lesen | |
| 03.09. | Lixte Biotechnology appoints new CFO and board members | 1 | Seeking Alpha |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,45 | +0,58 % | BioNTech startet durch: 62% Kurspotenzial winken | BioNTech sorgt mit positiven Phase-3-Daten zum Antikörper Gotistobart für Aufsehen in der Krebsforschung. Analysten sehen hohes Kurspotenzial, insbesondere durch die Pipeline-Innovationen in der Onkologie... ► Artikel lesen | |
| EVOTEC | 5,246 | +1,47 % | Evotec Aktie: Finaler Selloff? - Circus, Hensoldt, Nordex, Rheinmetall und TUI im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,600 | +2,15 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,120 | -4,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,300 | +7,88 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| MAINZ BIOMED | 1,080 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,615 | +1,33 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| IMMUNITYBIO | 1,815 | +1,20 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,100 | 0,00 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,685 | 0,00 % | Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet | ||
| CEL-SCI | 4,520 | -1,74 % | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 | Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive... ► Artikel lesen | |
| ORAGENICS | 0,825 | -0,42 % | ORAGENICS INC - 8-K, Current Report | ||
| CAPRICOR | 21,850 | -1,58 % | Piper Sandler reiterates Capricor stock rating, names it 2026 top pick | ||
| FIBROGEN | 7,700 | +1,99 % | FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration | Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,002 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.